Trials / Conditions / Platinum-resistant Ovarian Cancer (PROC)

Platinum-resistant Ovarian Cancer (PROC)

6 registered clinical trials studyying Platinum-resistant Ovarian Cancer (PROC) — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Safety and Efficacy of RIF Combined With Anlotinib in the Treatment of Patients With Advanced Recurrent Platin NCT07075250	Peking University People's Hospital	Phase 4
Not Yet Recruiting	Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Ca NCT06600841	Fujian Cancer Hospital	Phase 2
Active Not Recruiting	Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432	Nuvation Bio Inc.	Phase 1 / Phase 2
Recruiting	A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Co NCT05824975	GI Innovation, Inc.	Phase 1 / Phase 2
Recruiting	Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366	Genmab	Phase 1 / Phase 2
Terminated	A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Ad NCT03311334	Sumitomo Pharma America, Inc.	Phase 1 / Phase 2